Management Changes – Saudi Mirror http://www.saudimirror.com News On-line Mon, 25 Mar 2024 11:00:00 +0000 en-US hourly 1 https://wordpress.org/?v=5.3.2 Cellebrite Hires Marketing Veteran David Gee as Chief Marketing Officer, Ushering in Next Phase of Growth, Scale and Market Leadership http://www.saudimirror.com/?p=218472/ http://www.saudimirror.com/?p=218472/#respond Mon, 25 Mar 2024 11:00:00 +0000 http://www.saudimirror.com/?p=218472 TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 25, 2024 (GLOBE NEWSWIRE) — Cellebrite DI Ltd (Nasdaq: CLBT), a global leader in Digital Investigative solutions for the public and private sectors, today announced the appointment of David Gee as Chief Marketing Officer (CMO). Mr. Gee brings more than 25 years of global sales and marketing expertise and will serve as a member of Cellebrite’s executive leadership team, reporting directly to CEO Yossi Carmil. He will oversee Cellebrite’s global marketing strategy and execution to help the Company capitalize on the major growth opportunities ahead in the digital investigations marketplace.

Mr. Gee joins Cellebrite as digital crimes escalate exponentially, and criminal activities become more sophisticated, requiring law enforcement and enterprises to apply more advanced tools to fully capture, manage and analyze all the digital evidence at their disposal. Cellebrite’s end–to–end Case–to–Closure (C2C) platform helps investigative teams in both public and private sectors reach time–to–evidence quicker and close cases faster, smarter and more defensibly than ever before.

“Cellebrite stands on the precipice of an unparalleled opportunity. As we forge ahead, scaling our extraordinary growth, we welcome aboard David Gee, a strategic marketing luminary,” said Yossi Carmil, Cellebrite CEO. “His seasoned expertise will propel our global expansion. David embodies our vision and champions the ethical and responsible use of technology, recognizing its power to safeguard our world. Together, we’ll redefine what’s possible.”

As a seasoned industry veteran, Mr. Gee brings a wealth of experience to his role as CMO. His previous roles have left indelible marks, and now he’s ready to propel Cellebrite to new heights. Most recently, he served as CMO at Coherent Inc. where he digitally transformed the business and was part of the management team that doubled the market capitalization within two years. Previously, David was CMO at Imperva, Zuora and Infoblox and held senior marketing and operational roles at Hewlett Packard, Yahoo!, Sun Microsystems and IBM.

“It is rare to find an opportunity that fits my personal values, while also aligning with my skill set. I am thrilled to join Cellebrite and become part of such an important, mission–based business,” said Mr. Gee. “Cellebrite’s achievements to date are inspiring, and the opportunities ahead to further accelerate justice are exciting. I look forward to working with my new colleagues as we focus on executing the programs, campaigns, and initiatives that will broaden market awareness and adoption of the Company’s innovative digital investigative solutions.”

To learn more about Cellebrite and its Case–to–Closure Platform, please visit www.cellebrite.com.

About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Investigative platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on X at @Cellebrite.

References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Caution Regarding Forward Looking Statements

This document includes “forward–looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward–looking statements include, but are not limited to, the following: helping our team further expand our business around the world; and executing the programs, campaigns and initiatives that will broaden market awareness of the Company’s innovative digital investigative solutions, fortify and expand our customer relationships globally, increase our market leadership and achieve our business objectives. Such forward–looking statements are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward–looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add–ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e–commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel–Hamas war and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti–corruption, trade compliance, anti–money–laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20–F filed with the SEC on March 21, 2024 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward–looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward–looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Media 

Victor Cooper 
Sr. Director of Corporate Communications + Content Operations 
Victor.cooper@cellebrite.com 
+1 404.804.5910 

Investor Relations 

Andrew Kramer 
Vice President, Investor Relations 
investors@cellebrite.com 
+1 973.206.7760

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dd321307–8ce5–4237–86b7–324ddbd27380


GLOBENEWSWIRE (Distribution ID 9078473)

]]>
http://www.saudimirror.com/?p=218472/feed/ 0
Recursion Announces Plans to Open New Office in London http://www.saudimirror.com/?p=218388/ Mon, 11 Mar 2024 08:00:00 +0000 http://www.saudimirror.com/?p=218388 LONDON, March 11, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London’s vibrant King’s Cross neighborhood. Set to formally open in June 2024, the site will provide Recursion and Valence Labs, the company’s artificial intelligence research engine, access to world–class talent across Europe’s rapidly growing TechBio sector and embed Recursion in a thriving innovation ecosystem of leading technology and life science companies.

“As Recursion continues to lead and define the TechBio industry, it's critical we hire the best possible talent, much of which is located in Europe,” said Chris Gibson, Ph.D., Co–founder and CEO at Recursion. “London stood out as an ideal location given its brilliant and interdisciplinary talent across the fields of technology, biology and chemistry. It’s also the epicenter for the rapidly growing TechBio sector in Europe, where leading technology and life science companies like Google and Merck both sit within walking distance of our new Recursion site. I look forward to expanding our operations in Europe and hiring many new Recursionauts who will help us advance our mission of decoding biology to radically improve lives.”

To support Recursion’s leadership in TechBio and entry into London, the company is excited to announce the addition of Michael Bronstein, DeepMind Professor of Artificial Intelligence at Oxford University, as a Scientific Advisor. Professor Bronstein is a world leader in geometric deep learning, graph neural networks, and protein design. Professor Bronstein joins AI luminary Professor Yoshua Bengio in supporting Recursion and Valence Labs in the development of state–of–the–art AI models to support the industrialization of drug discovery.

“Recursion is leading the field in advancing cutting–edge AI research for real–world applications with the potential to radically improve lives, and I’m honoured to join them in their mission,” said Prof Michael Bronstein. “I have collaborated with Valence prior to their acquisition by Recursion, and I look forward to continuing to work with the team to advance this important work, especially as Recursion continues to grow in London.”

Recursion’s 6,700 square foot London office will be located at 3 Pancras Square, King’s Cross London. The building is part of a 67–acre redevelopment project in the heart of King’s Cross, with over 4.5 million square feet of office space. Located within a 3–minute walk from King’s Cross Station and St. Pancras International, the site offers excellent transit access. The building includes an onsite cafe, bicycle storage, showers, prayer room and mothers room. In line with Recursion’s commitment to sustainability, the building meets the requirements for an “Excellent” rating by BREEAM building standards and is linked to a site–wide district heating and cooling network that results in net–zero carbon emissions.

“The UK Government’s plan for attracting more inward investment into the UK is working. Recursion’s investment is yet another vote of confidence in the UK, our top talent and our amazing tech and life sciences industries,” said Investment Minister Lord Johnson. “I’m delighted Recursion has chosen London, and we’ll continue to do everything we can to ensure the UK remains the top choice for investments like this.”

Today, Recursion has over 500 employees with a near–equal mix of life scientists and technologists across sites in Salt Lake City, Toronto, Montréal, and the San Francisco Bay Area. Recursion’s new London office will serve as an extension of both Recursion and Valence Labs’ teams. To launch recruiting efforts for the new site, Recursion has opened multiple new roles across technology and biology functions with immediate plans to hire the first 20 people to be based out of the new London office. Recursion and Valence Labs will also host a TechBio Mixer tomorrow, March 12, at the location of its new site to celebrate the office and network with the TechBio community.

For more information on open positions and to apply, visit recursion.com/careers and valencelabs.com/careers.

About Recursion
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient–centric datasets. Recursion leverages sophisticated machine–learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, chemistry and patient–centric data to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward–Looking Statements
This document contains information that includes or is based upon “forward–looking statements'' within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the opening of the London office and timing of such opening; the recruitment efforts and number of roles at the London office; and all other statements that are not historical facts. Forward–looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “could,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10–K for the Fiscal Year Ended December 31, 2023. All forward–looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

 


GLOBENEWSWIRE (Distribution ID 9060948)

]]>
Curia nomme Steve Lavezoli vice-président de sa division Produits biologiques http://www.saudimirror.com/?p=218291/ Fri, 23 Feb 2024 20:05:20 +0000 http://www.saudimirror.com/?p=218291 ALBANY, New York, 23 févr. 2024 (GLOBE NEWSWIRE) — Curia, l’un des principaux organismes de recherche, de développement et de fabrication sous contrat, a annoncé aujourd’hui la nomination de Steve Lavezoli au poste de vice–président des produits biologiques à compter du 26 février. M. Lavezoli dirigera la division des produits biologiques de Curia, dont il supervisera les services de découverte, de développement et de fabrication.

« C’est une période passionnante pour notre équipe en charge des produits biologiques, et nous sommes ravis que Steve rejoigne nos rangs », a déclaré Philip Macnabb, PDG de Curia. « L’expérience remarquable de Steve à la direction des opérations commerciales pour le développement et la fabrication de produits biologiques fait de lui un candidat naturel pour piloter nos initiatives dans le domaine des produits biologiques. Sous sa direction, je suis persuadé que nous poursuivrons notre mission dévolue aux sciences de la vie qui changent la vie. »

M. Lavezoli a récemment travaillé pour Scorpius Biologics, une start–up CDMO (organisation de développement et de fabrication sous contrat de médicaments) spécialisée dans le développement et la fabrication de produits biologiques microbiens et mammifères, en tant que vice–président des opérations commerciales. Avant de rejoindre Scorpius, il a passé quatre années chez Catalent Biologics, où il a concentré ses efforts sur le développement commercial des substances médicamenteuses aux États–Unis pour les programmes cliniques en phase initiale, puis sur l’intégration des programmes commerciaux en phase finale. Il a également passé 12 ans dans l’industrie des gaz industriels au sein de Linde Gas avant de rejoindre W.L. Goren, au sein de sa division biopharmaceutique en démarrage à un poste de développement des affaires commerciales et du marché des substances médicamenteuses en vrac à usage unique. Il est titulaire d’une licence en génie chimique de l’université d’État de Pennsylvanie.

« Curia occupe une position unique dans le secteur des CDMO, avec une offre de bout en bout impressionnante », a déclaré M. Lavezoli. « C’est un honneur de rejoindre une équipe dotée d’une expertise scientifique aussi approfondie et d’une volonté aussi forte d’avoir un impact positif sur la vie des patients. »

Pour en savoir plus sur les offres de produits biologiques de Curia, cliquez ici : https://curiaglobal.com/biologics/

À propos de Curia
Curia est une organisation de développement et de fabrication sous contrat (« CDMO ») avec plus de 30 ans d’expérience, un réseau intégré de 27 sites dans le monde et plus de 3 500 collaborateurs travaillant en partenariat avec les clients biopharmaceutiques pour mettre sur le marché des thérapies qui changent la vie. Notre offre de produits biologiques et de petites molécules couvre le cycle complet de la découverte jusqu’à la commercialisation, avec des capacités réglementaires et analytiques intégrées. Nos scientifiques, nos experts en processus et nos installations de pointe apportent une expérience de premier ordre dans la fabrication de substances et de produits pharmaceutiques. De la curiosité au traitement, nous exécutons toutes les étapes pour améliorer la vie des patients. Consultez notre site à l’adresse www.curiaglobal.com.

Contact de l’entreprise :
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Une photo accompagnant ce communiqué de presse est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/f9784607–495c–40d3–9e39–b65c8147d1c5


GLOBENEWSWIRE (Distribution ID 9042529)

]]>
Curia Nomeia Steve como Vice-Presidente, Divisão Biológica http://www.saudimirror.com/?p=218290/ Fri, 23 Feb 2024 20:05:20 +0000 http://www.saudimirror.com/?p=218290 ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) — A Curia, uma organização líder em pesquisa, desenvolvimento e fabricação por contrato, anunciou hoje a nomeação de Steve Lavezoli como vice–presidente da divisão biológica a vigorar a partir de 26 de fevereiro. Lavezoli liderará a divisão de produtos biológicos da Curia, supervisionando seus serviços de descoberta, desenvolvimento e fabricação.

“Este é um momento emocionante para a nossa equipe de produtos biológicos, e temos muito prazer em ter Steve a bordo”, disse o CEO da Curia, Philip Macnabb. “A vasta experiência de Steve com liderança de operações comerciais para desenvolvimento e fabricação de produtos biológicos o torna perfeito para liderar nossos esforços de produtos biológicos. Sob sua orientação, estou certo de que promoveremos nossa missão de mudar a vida das ciências da vida.”

Lavezoli trabalhou recentemente na Scorpius Biologics, uma startup de CDMO focada no desenvolvimento e fabricação de produtos biológicos microbianos e de mamíferos como vice–presidente de operações comerciais. Antes de ingressar na Scorpius, ele passou quatro anos na Catalent Biologics, focado no desenvolvimento de negócios de medicamentos nos EUA para programas clínicos em estágio inicial e, posteriormente, focado na integração de programas comerciais em estágio avançado. Ele também passou 12 anos na indústria de gases industriais na Linde Gas antes de ingressar na W.L. Gore na nova divisão biofarmacêutica para ocupar a função de desenvolvimento comercial/de mercado em itens de uso único de medicamentos a granel. Ele fez bacharelado em engenharia química na Pennsylvania State University.

“A Curia ocupa uma posição única na indústria de CDMO com uma impressionante oferta integral”, disse Lavezoli. “É uma honra fazer parte de uma equipe com um conhecimento científico tão profundo e um propósito orientado por valores para gerar um impacto positivo na vida dos pacientes.”

Saiba mais sobre as ofertas de produtos biológicos da Curia aqui: https://curiaglobal.com/biologics/

Sobre a Curia
A Curia é uma Organização de Desenvolvimento e Fabricação por Contratos (CDMO) com mais de 30 anos de experiência, uma rede integrada de 27 locais em todo o mundo e mais de 3.500 funcionários em parcerias com clientes biofarmacêuticos para lançar no mercado terapias que mudam a vida. Nossas ofertas de produtos biológicos e moléculas pequenas abrangem a descoberta através da comercialização, com capacidades regulatórias e analíticas integradas. Nossos especialistas científicos e de processos, e instalações de última geração oferecem a melhor experiência em fabricação de medicamentos e produtos farmacêuticos. Da curiosidade à cura, proporcionamos todas as etapas para a melhoria da vida dos pacientes. Visite–nos em curiaglobal.com.

Contato Corporativo:
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Foto deste comunicado disponível em: https://www.globenewswire.com/NewsRoom/AttachmentNg/f9784607–495c–40d3–9e39–b65c8147d1c5


GLOBENEWSWIRE (Distribution ID 9042529)

]]>
Curia ernennt Steve Lavezoli zum Vice President, Biologika http://www.saudimirror.com/?p=218289/ Fri, 23 Feb 2024 20:05:20 +0000 http://www.saudimirror.com/?p=218289 ALBANY, New York, Feb. 23, 2024 (GLOBE NEWSWIRE) — Curia, ein führendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen, hat heute bekanntgegeben, dass Steve Lavezoli mit Wirkung vom 26. Februar zum Vice President, Biologika, ernannt wurde. Herr Lavezoli wird die Biologika–Abteilung von Curia leiten und die Bereiche Entdeckung, Entwicklung und Herstellung beaufsichtigen.

„Dies ist eine aufregende Zeit für unser Biologika–Team, und wir freuen uns, Herrn Lavezoli an Bord zu haben“, so Philip Macnabb, CEO von Curia. „Die bemerkenswerte Erfahrung von Herrn Lavezoli in der Leitung kommerzieller Operationen für die Entwicklung und Herstellung von Biologika macht ihn zu einer natürlichen Wahl für die Leitung unserer Biologika–Aktivitäten. Ich bin zuversichtlich, dass wir unter seiner Führung unseren Auftrag, die Biowissenschaften zu verändern, weiter vorantreiben werden.“

Herr Lavezoli war zuletzt als Vice President of Commercial Operations bei Scorpius Biologics tätig, einem Startup–CDMO, das sich auf die Entwicklung und Herstellung von mikrobiellen und Säugetier–Biologika konzentriert. Bevor er zu Scorpius kam, verbrachte er vier Jahre bei Catalent Biologics, wo er sich auf die Geschäftsentwicklung von Arzneimittelsubstanzen in den USA für klinische Programme in der Frühphase und später auf die Integration kommerzieller Programme in der Spätphase konzentrierte. Darüber hinaus war er 12 Jahre in der Industriegasebranche bei Linde Gas tätig, bevor er zu W.L. Gore in die Startup–Biopharmazie–Abteilung wechselte, wo er an einer kommerziellen Geschäfts–/Marktentwicklungsfunktion für Einwegartikel mit Bulk–Arzneimitteln arbeitete. Er erwarb seinen B.S. in Chemietechnik an der Pennsylvania State University.

„Curia hat eine einzigartige Position in der CDMO–Branche mit einem beeindruckenden ganzheitlichen Angebot“, so Lavezoli. „Es ist eine Ehre, in einem Team mit so großer wissenschaftlicher Expertise und einem werteorientierten Ziel zu arbeiten, um das Leben von Patienten positiv zu beeinflussen.“

Erfahren Sie hier mehr über das Biologika–Angebot von Curia: https://curiaglobal.com/biologics/

Über Curia
Curia ist ein Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen (CDMO) mit mehr als 30 Jahren Erfahrung, einem integrierten Netzwerk aus 27 globalen Standorten und über 3.500 Mitarbeitern, das mit Kunden aus dem Bereich der Biopharmazie zusammenarbeitet, um lebensverändernde Therapien auf den Markt zu bringen. Unser Angebot an Biologika und kleinen Molekülen reicht von der Entdeckung bis zur Vermarktung und umfasst integrierte regulatorische und analytische Kompetenzen. Unsere wissenschaftlichen und verfahrenstechnischen Experten sowie unsere hochmodernen Anlagen bieten erstklassige Erfahrung in der Herstellung von Wirkstoffen und Arzneimitteln. Von der Neugierde bis zur Heilung leisten wir jeden Schritt, um das Leben der Patienten zu verbessern. Besuchen Sie uns unter curiaglobal.com.

Kontakt zum Unternehmen:
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Ein Foto zu dieser Mitteilung ist verfügbar unter: https://www.globenewswire.com/NewsRoom/AttachmentNg/f9784607–495c–40d3–9e39–b65c8147d1c5


GLOBENEWSWIRE (Distribution ID 9042529)

]]>
Curia Appoints Steve Lavezoli as Vice President, Biologics http://www.saudimirror.com/?p=218283/ Fri, 23 Feb 2024 14:00:00 +0000 http://www.saudimirror.com/?p=218283

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26. Lavezoli will lead Curia’s biologics division, overseeing its discovery, development and manufacturing services.

“This is an exciting time for our biologics team, and we are pleased to have Steve on board,” said Curia CEO Philip Macnabb. “Steve’s remarkable breadth of experience leading commercial operations for biologics development and manufacturing makes him a natural fit to lead our biologics efforts. Under his guidance, I have every confidence that we will further our mission of life–changing life science.”

Lavezoli most recently worked for Scorpius Biologics, a startup CDMO focused on microbial and mammalian biologics development and manufacturing as the vice president of commercial operations. Prior to joining Scorpius, he spent four years with Catalent Biologics, focused on drug substance business development in the U.S. for early–stage clinical programs and later focusing on late–stage commercial program integration. He also spent 12 years in the industrial gasses industry with Linde Gas before joining W.L. Gore in the startup biopharmaceutical division to work on a commercial business/market development role for bulk drug substance single–use items. He earned his B.S. in chemical engineering from Pennsylvania State University.

“Curia holds a unique position in the CDMO industry with an impressive end–to–end offering,” said Lavezoli. “It’s an honor to join a team with such deep scientific expertise and values–driven purpose to drive a positive impact on patients’ lives.”

Learn more about Curia’s biologics offerings here: https://curiaglobal.com/biologics/

About Curia
Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with biopharmaceutical customers to bring life–changing therapies to market. Our biologics and small molecule offerings span discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state–of–the–art facilities deliver best–in–class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to improve patients’ lives. Visit us at curiaglobal.com.

Corporate Contact:
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/f9784607–495c–40d3–9e39–b65c8147d1c5


GLOBENEWSWIRE (Distribution ID 9041965)

]]>
Halo Investing Appoints Hashbeer Ali as Executive Vice President – Institutional Sales, Middle East & Africa http://www.saudimirror.com/halo-investing-appoints-hashbeer-ali-as-executive-vice-president-institutional-sales-middle-east-africa/ Thu, 05 Oct 2023 17:07:10 +0000 http://www.saudimirror.com/?p=217174 CHICAGO, Oct. 05, 2023 (GLOBE NEWSWIRE) — Halo Investing ("Halo"), an award–winning platform for Protective Investments, is delighted to announce the appointment of Hashbeer Ali as Executive Vice President "" Institutional Sales for the Middle East & Africa at Halo Investing MEA Ltd., a regulated entity by ADGM's Financial Services Regulatory Authority. With a career spanning more than two decades in banking and derivatives sales, Hashbeer brings a wealth of experience and expertise to the Halo team.

Mr. Ali's extensive career in the financial industry has been marked by a commitment to excellence and a deep understanding of derivatives markets. His background includes notable engagements with local banks, where he played a pivotal role in shaping and executing derivative strategies. His proven track record of delivering exceptional results and building strong client relationships aligns seamlessly with Halo Investing's mission to grow access to innovative investment solutions.

"We are thrilled to welcome Hashbeer Ali to the Halo family," said Sadiq Hussain, Senior Executive Officer. "His impressive background and industry knowledge will be instrumental in advancing our institutional sales efforts and driving our mission to revolutionize the way structured investment products are accessed and managed."

Hashbeer Ali's appointment reinforces Halo Investing's commitment to building a team of industry leaders dedicated to delivering cutting–edge investment solutions to clients throughout the Middle East and Africa. His role as Executive Vice President "" Institutional Sales will encompass developing and executing strategic sales initiatives while strengthening Halo's presence in the institutional marketplace.

"I am excited to join Halo Investing, a company that is at the forefront of innovation in the structured investment space," Hashbeer Ali commented. "I look forward to leveraging my experience to contribute to Halo's continued growth and success."

Hashbeer Ali's addition to the Halo team is a significant milestone, marking the company's ongoing expansion and dedication to providing institutional clients with access to innovative and tailored investment solutions.

For media inquiries, please contact:

Halo Investing
Vladislav Moldavskiy
vlad.moldavskiy@haloinvesting.com

About Halo Investing

Halo Investing MEA Ltd. ("Halo MEA") is licensed and regulated by Abu Dhabi Global Market ("ADGM")'s Financial Services Regulatory Authority ("FSRA"). Halo MEA is a wholly owned subsidiary of Halo Investing, Inc. and authorized to provide financial services to professional clients and market counterparties only. Halo MEA acts solely as a distributor/selling agent and is not the issuer or guarantor of any structured product. For more information, please visit: http://www.haloinvesting.ae.

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/8c4652d5–bdee–478f–aa1a–ba37dd83f351


GLOBENEWSWIRE (Distribution ID 8944629)

]]>
William Ruto, President of Kenya, joins GCA Advisory Board http://www.saudimirror.com/william-ruto-president-of-kenya-joins-gca-advisory-board/ Fri, 29 Sep 2023 07:08:21 +0000 http://www.saudimirror.com/?p=217117 Nairobi, Kenya, Sept. 29, 2023 (GLOBE NEWSWIRE) — William Ruto, President of the Republic of Kenya and Chair of the Committee of African Heads of State and Government on Climate Change has accepted an invitation from Ban Ki–moon, 8th Secretary–General of the United Nations and Chair of the Global Center on Adaptation (GCA) and CEO Professor Patrick Verkooijen, to join the GCA Advisory Board.

During a high–level official meeting which took place today at the State House in Nairobi , Professor Patrick Verkooijen and President Ruto discussed a roadmap to guide the mobilisation of the financial commitments for adaptation which were made at the Africa Climate Summit hosted by the President in Nairobi earlier this month.

The Africa Adaptation Acceleration Program (AAAP) Country Compacts, announced during the Leaders' Dialogue on Adaptation, will drive the doubling down and scaling of adaptation action across the world's most climate–vulnerable continent. The country–led investment roadmaps, initiated by the Government of Kenya, outline adaptation investment priorities, financing needs, and finance mobilization strategies for implementing climate adaptation measures connected to the priorities outlined in National Adaptation Plans and other national strategies.

Recent research from GCA showed Africa may need a nearly tenfold increase in climate adaptation funding to $100 billion a year if it is to buttress its infrastructure, improve climate early warning systems and shield its agriculture from climate change.

On accepting the invitation, William Ruto, President of the Republic of Kenya said:
"African governments, businesses and communities have paid heavily for climate–related destruction and disruption, and have already invested heavily in adaptation action, but we need stronger international partnerships to support adaptation more than ever before. The Africa Adaptation Acceleration Program , the world's largest adaptation program resulting from collaboration between GCA, the University of Nairobi, African Development Bank and the African Union Commission, is the best vehicle we have to mobilize additional funding. I look forward to working closely with Professor Verkooijen and the Board to build on the US$6.7 billion that the AAAP has already invested in resilient climate projects in 27 countries since 2021. By working together I am confident that we will make great progress in ensuring that international commitments to deliver highly strategic and comprehensive adaptation responses are fulfilled."

Professor Patrick Verkooijen, CEO of GCA and Distinguished Chair of the Wangari Maathai Institute said:
"It is only by adapting to climate change that Africa can reach its potential. Yet promised climate finance""which is necessary to underpin wider development goals""remains critically short of what is needed. President Ruto has played a crucial role in the implementation of the Africa Adaptation Acceleration Program across the continent and I commend his leadership in hosting the Africa Climate Summit. I look forward to our continued collaboration to ensure the Summit outcomes are delivered for Africa's march to sustainable economic transformation and green growth."

During the Africa Climate Summit, President Ruto announced Kenya will host regional headquarters for GCA in Nairobi:
"I have had opportunity to interact with the Global Center for Adaptation, an international organisation based in Rotterdam in the Netherlands, whose constitution is an appealing emblem of our aspirations, from the aspirational design of its global headquarters and futuristic regional headquarters in Nairobi, comprising green walls and roof as well as rain gardens, to the collaborative culture of its staff. Unsurprisingly, the Center is intended to inspire the world to thrive with nature instead of pursuing the dangerous course of seeking to thrive at nature's expense."

It is expected the new Africa headquarters will open in Nairobi in January 2025.

Notes to Editors

About the Global Center on Adaptation
The Global Center on Adaptation (GCA) is an international organization that works as a solutions broker to accelerate action and support for adaptation solutions, from the international to the local, in partnership with the public and private sectors. Founded in 2018, GCA operates from the largest floating office in the world, located in Rotterdam, the Netherlands. GCA has a worldwide network of regional offices in Abidjan, Cote d'Ivoire; Dhaka, Bangladesh, and Beijing, China.

About the Africa Adaptation Acceleration Program
The Africa Adaptation Acceleration Program (AAAP) is a joint initiative of the African Development Bank and the Global Center on Adaptation (GCA). It aims to mobilize $25 billion, over five years, to accelerate and scale climate adaptation action across the continent. This ambition is delivered through the AAAP Upstream Financing Facility managed by the Global Center on Adaptation and the African Development Bank's climate action window in the ADF replenishment. AAAP works across four pillars to achieve transformational results: Climate–Smart Digital Technologies for Agriculture and Food Security; African Infrastructure Resilience Accelerator; Youth Empowerment for Entrepreneurship and Job Creation in Climate Adaptation and Resilience and Innovative Financial Initiatives for Africa.

Attachment


GLOBENEWSWIRE (Distribution ID 8930853)

]]>
Impulse Dynamics Announces Leadership Changes http://www.saudimirror.com/impulse-dynamics-announces-leadership-changes/ Tue, 19 Sep 2023 11:17:08 +0000 http://www.saudimirror.com/?p=217020 MARLTON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, announced new leadership appointments, including Jason Spees to Chief Executive Officer, Shlomi Nachman to Chairman of the Board, and John Liddicoat, M.D., as a member of the Board of Directors. Spees was recently President and Chief Commercial Officer at Impulse Dynamics and brings a depth of medical device industry experience from commercial leadership roles. Nachman most recently was the Company Group Chairman at Johnson & Johnson, overseeing the Cardiovascular and Specialty Solutions & Vision Group. Liddicoat most recently served as Executive Vice President and President of the Americas Region and Enterprise Technology & Innovation function at Medtronic.

"I am pleased to lead the Impulse Dynamics team, focusing on a strong commercialization strategy and our commitment to an ongoing pace of innovation to change the course of treatment for patients living with heart failure," said Spees. "We find ourselves in a unique position to capitalize on robust clinical data and a lineup of cutting–edge technologies, exemplified by the Integra–D trial featuring the groundbreaking single device that integrates our CCM technology with implantable cardioverter defibrillator (ICD) technology. I look forward to working closely with the board and the leadership team to optimize the company for its next phase of commercial acceleration."

"I am honored to join the board of an organization that has showcased substantial contributions to the advancement of heart failure treatment," said Shlomi Nachman. "Over 64 million people suffer from heart failure, and many of those treated are not experiencing the higher quality of life they deserve. With CCM therapy and its future product pipeline, we are in the exciting position of being able to help millions of these patients to feel better and lead fuller lives," Nachman added. "I'm looking forward to working with the leadership team and the board to ensure a direct path to ongoing innovation and commercial success."

"I've been watching Impulse Dynamics and its technology from the sidelines for many years, and I am excited to now be able to join the team," said Liddicoat. "I look forward to working with a strong leadership team to lead innovation–driven growth as we aim to enhance the standard of care for heart failure patients across the globe."

Jason Spees joined the company as President and Chief Commercial Officer in July 2021. He brings more than two decades of successful leadership roles in the medical device industry. Spees was most recently Senior Vice President of Sales and Marketing for Biotronik in the areas of cardiac rhythm management, cardiovascular intervention, peripheral vascular intervention, diagnostics, and digital health. Prior to Biotronik, Spees was the Chief Commercial Officer of Preventice Solutions, along with multiple leadership positions, including Vice President of Sales for Boston Scientific. He holds a B.S. in Operations Research and Engineering from the United States Air Force Academy and an M.A. in Public Management – Finance from the University of Maryland.

Shlomi Nachman was the Company Group Chairman of Cardiovascular and Specialty Solutions and Visions Group within Johnson & Johnson's Medical Devices sector. Nachman was a member of the Medical Devices Group Operating Committee, where he led a diverse portfolio of six medical device businesses, including Electrophysiology, Neurovascular Intervention, Ear, Nose & Throat, Breast Aesthetics, Optometry and Ophthalmology. Before that, Nachman had various roles with increased scope and responsibilities, including Worldwide President of Biosense Webster and Cordis. His career at Johnson & Johnson spanned over 27 years, comprising multiple leadership positions with a proven track record of success that has recognized the ability to drive growth, innovation, and architect business turnarounds. Additionally, Nachman has accrued deep knowledge in all aspects of medical devices, such as general management, strategy, L&A, finance, product development, operations, sales and marketing, and research and development. Nachman was born in Israel and holds a B.S. in Management and Economics from the Technion Institute, as well as a diploma in electrical engineering from the Amal Technical School.

John Liddicoat brings a history of transformational leadership focused on execution. He spent 16 years at Medtronic, driving the strategic direction and global operations of increasing size and scope, including the Structural Heart, Cardiac Rhythm, and Heart Failure businesses. In his most recent role as Executive Vice President and President of the Americas region and the Enterprise Innovation and Technology function, he was responsible for designing and implementing go–to–market strategies to deliver above–market growth across North and South America. Liddicoat graduated medical school from the University of Chicago, completed a residency in general and cardiothoracic surgery at Johns Hopkins Hospital, and served on the faculty of Harvard Medical School. An innovator and entrepreneur, he has also served as a consultant to venture capital firms and early–stage medical device companies.

About the Optimizer Integra CCM–D System and CCM Therapy

The Optimizer Integra CCM–D System is an investigational device that combines CCM therapy and ICD therapy into one device. This device is being used in an FDA–approved Investigational Device Exemption (IDE) study and is not available for sale in the United States.

Impulse Dynamics currently offers the Optimizer system that is FDA–approved and CE–marked. The Optimizer system delivers CCM therapy "" the company's proprietary technology "" to the heart. CCM therapy has been designed by Impulse Dynamics to improve the heart's contraction, allowing more oxygen–rich blood to be pushed out through the body. CCM therapy is indicated to improve the 6–minute hall walk, quality of life, and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline–directed medical therapy, are not indicated for CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent.

CCM therapy delivers non–excitatory electrical pulses from the implantable Optimizer device in a manner designed to improve heart contraction. CCM therapy sends unique electrical pulses to the heart cells during their absolute refractory period. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, and CCM therapy has been published in more than 120 peer–reviewed journal articles.

About Impulse Dynamics

Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in heart failure patients. CCM therapy is delivered through the Optimizer system, which includes an IPG implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 9,000 patients have received the therapy as part of clinical trials and real–world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com or follow the company on LinkedIn, Twitter, and Facebook.

Forward–Looking Statements

This press release contains forward–looking statements. All statements other than statements of historical facts contained in this press release are forward–looking statements. In some cases, you can identify forward–looking statements by terms such as ""may,'' ""will,'' ""should,'' ""expect,'' ""plan,'' ""anticipate,'' ""could,'' ""intend,'' ""target,'' ""project,'' ""contemplate,'' ""believe,'' ""estimate,'' ""predict,'' ""potential'' or ""continue'' or the negative of these terms or other similar expressions, although not all forward–looking statements contain these words. Forward–looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and CCM therapy combined with an ICD delivered via a single device (CCM–D), and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short–term and long–term benefits of the Optimizer Integra CCM–D System and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward–looking statements are based on management's current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward–looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company's future research and development costs, capital requirements and the company's needs for additional financing; commercial success and market acceptance of CCM therapy; the company's ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company's ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company's business model and strategic plans for its products, technologies and business, including its implementation thereof; the company's ability to expand, manage and maintain its direct sales and marketing organization; the company's ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company's ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward–looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward–looking statements contained herein. These forward–looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release.

###


GLOBENEWSWIRE (Distribution ID 8924737)

]]>
Gemcorp Capital appoints former UK Middle East Trade Commissioner to lead regional expansion http://www.saudimirror.com/gemcorp-capital-appoints-former-uk-middle-east-trade-commissioner-to-lead-regional-expansion/ Mon, 04 Sep 2023 03:30:00 +0000 http://www.saudimirror.com/?p=216880 DUBAI, United Arab Emirates, Sept. 03, 2023 (GLOBE NEWSWIRE) — Gemcorp Capital Management today announces its expansion in the Middle East. The new regional operation will be led by Simon Penney, formally His Majesty's Trade Commissioner for the Middle East for the UK Government. This strategic move reflects Gemcorp's continued commitment to building a local presence in the emerging markets and focus on the Middle East region's ambitious growth plans and investment opportunities.

Simon Penney's extensive experience and leadership will be instrumental in driving Gemcorp's origination and fundraising activities in the region and developing partnerships with Gulf investors and institutions to access projects across the emerging markets. Under his tenure as the UK's trade commissioner, trade with the region hit all–time highs alongside establishing multi–billion dollar investment partnerships with a number of Gulf countries. Simon has spent most of his career in the banking sector leading financial institutions across Europe, the Middle East, Africa and Asia. These included roles as: Head of Wholesale and International Banking at First Gulf Bank (UAE); CEO, Middle East and Africa at Royal Bank of Scotland; and CEO at ABN AMRO Bank (South Africa).

Gemcorp Capital's Chief Executive Officer, Atanas Bostandjiev, said: “The region's strategic location, robust infrastructure and business–friendly environment serve as an ideal gateway to access the exciting opportunities that the Middle East and surrounding regions have to offer. Developing a true partnership with local institutions is one of our key business principles. We look forward to applying our emerging markets expertise to investing in the region and aspire to become an important conduit between the Middle East and Africa and the wider emerging markets. With Simon at the helm of our regional business, we aim to become a regional partner of choice for infrastructure, technology and energy transition opportunities.”

Simon Penney expressed enthusiasm about the new role and the opportunities it presents: “I am excited to be leading Gemcorp Capital's operations in the Middle East. The region's crucial geographical and geopolitical position make it an ideal launchpad for Gemcorp Capital's continued growth.

“Gemcorp Capital has consistently demonstrated expertise in navigating the complexities of emerging markets, fostering capital investment and job creation and generating sustainable returns for its investors."

About Gemcorp Capital Management

Gemcorp Capital is as an independent investment management firm focused on emerging markets. Gemcorp Capital has facilitated over US$7 billion worth of investments in credit and equity transactions since inception. The firm is looking to invest at least $10 billion in Africa over the next decade, mainly in the form of debt deals in partnership with other institutional investors.

Media Enquiries:

gemcorp@citigatedewerogerson.com


GLOBENEWSWIRE (Distribution ID 8915072)

]]>